Cell and antibody therapies targeting HLA-G
On December 19, 2022, the FDA approved the Phase I/IIa clinical trial application of IVS-3001,...
Feb 14, 2023
TCR therapy targeting MAGE-A4
Figure 1. MAGE-A4 Protein Recently at the 2022 CTOS Conference, Adaptimmune announced the SPEARHEAD-1 clinical...
Jan 02, 2023
AET San Diego 2022
KACTUS will be at the Antibody Engineering & Therapeutics conference in San Diego December 4-8th....
Nov 28, 2022